

Patient Name		<b>Kent &amp; Medway SACT proforma</b>		Date Calculated →	Protocol Number <b>HAEM-NHL-020</b>
Patient Number		<p align="center"><b>ICE</b></p> <p align="center"><b>Non-Hodgkin's Lymphoma</b></p> <p align="center"><b>Curative / Non-curative / Remission</b></p> <p align="center">Cycle No.....</p> <p align="center">(Repeat every 21 days)</p> <p align="center">Length of cycle: 3 weeks</p> <p align="center">No. cycles: max 3</p>		Height (m)	Authorising Consultant: <i>S Rassam / J Lindsay</i>
DOB				Weight (kg)	Pharmacist: J. Sawyer/O. Okuwa
Consultant				Surface Area (m <sup>2</sup> )	Review by October 2015 Version 1
			Allergies:		

- Notes**
- Haematological - Proceed with next course when neutrophils > 1.0 x 10<sup>9</sup>/L and platelets > 50 x 10<sup>9</sup>/L.
  - Renal - Ifosfamide: CrCl 40-60 ml/min give 70% dose; CrCl < 40 ml/min clinical decision.  
Etoposide: CrCl 50-15ml/min dose at 75%; CrCl < 15ml/min dose at 50%.
  - Hepatic - Etoposide: bilirubin 26-51µmol/L or AST 60-180 units give 50%; bilirubin > 51µmol/L or AST > 180 units is a clinical decision.  
Ifosfamide: bilirubin > 17µmol/L or ALP > 2.5ULN is a clinical decision.
  - Neurotoxicity - Grade 1 reduce dose of Ifosfamide to 3000mg/m<sup>2</sup> for the next cycle. If ≥ grade 2 toxicity occurs despite dose reduction, omit Ifosfamide.
  - Monitor urine for blood and increase Mesna if blood detected.

Day	Drug	Dose	Route	Infusion Duration	Administration Details	Batch No	Nurses Signature	Start Time	Stop Time
Day 1 ...../...../.....	Ondansetron	8mg	po	stat					
	Hydrocortisone	100mg	iv	stat					
	<b>ETOPOSIDE (100mg/m<sup>2</sup>)</b>		iv	60 min	NaCl 0.9% 500ml-1000ml.				

Prescriber's Signature & Date:	Pharmacist's Clinical Screen & Date:	Final release signature & Date:	Page 1 of 4
--------------------------------	--------------------------------------	---------------------------------	-------------

**Disclaimer:** This document is for use only within Kent and Medway. No responsibility will be accepted for the accuracy of this information when used elsewhere.

Patient Name		<b>Kent &amp; Medway SACT proforma</b>  <b>ICE</b> <b>Non-Hodgkin's Lymphoma</b> <b>Curative / Non-curative / Remission</b> Cycle No..... (Repeat every 21 days) Length of cycle: 3 weeks No. cycles: max 3					Date Calculated	Protocol Number <b>HAEM-NHL-020</b>	
Patient Number							Height (m)	Authorising Consultant: <i>S. Rassam / J. Lindsay</i>	
DOB		Weight (kg)	Pharmacist: <i>J. Sawyer/O. Okuwa</i>						
Consultant		Surface Area (m <sup>2</sup> )	Review by October 2015 Version 1						
Notes		Allergies:							
• Ifosfamide (5000mg/m <sup>2</sup> ) to run concurrently with Mesna (5000mg/m <sup>2</sup> ), given over 24 hours									
Day	Drug	Dose	Route	Infusion Duration	Administration Details	Batch No	Nurses Signature	Start Time	Stop Time
Day 2	Dexamethasone	8mg	po	stat					
.../.../...	Ondansetron	8mg	po	stat					
	ETOPOSIDE (100mg/m <sup>2</sup> )		iv	60 min	NaCl 0.9% 500ml-1000ml				
	CARBOPLATIN (AUC 5 max 800mg)		iv	1 hour	Glucose 5% 500ml				
	IFOSFAMIDE (5000mg/m <sup>2</sup> ) every 24 hours (to run concurrently with MESNA)		iv	24 hours	NaCl 0.9% 1000ml				
	MESNA (5000mg/m <sup>2</sup> ) over 24 hours		iv	24 hours	NaCl 0.9% 1000ml				
Prescriber's Signature & Date:			Pharmacist's Clinical Screen & Date:			Final release signature & Date:			Page 2 of 4

Disclaimer: This document is for use only within Kent and Medway. No responsibility will be accepted for the accuracy of this information when used elsewhere.

Patient Name		<b>Kent &amp; Medway SACT proforma</b>  <b>ICE</b> <b>Non-Hodgkin's Lymphoma</b> <b>Curative / Non-curative / Remission</b> Cycle No.: ..... (Repeat every 21 days) Length of cycle: 3 weeks No. cycles: max 3				Date Calculated →		Protocol Number <b>HAEM-NHL-020</b>	
Patient Number						Height (m)		Authorising Consultant: S Rassam / J Lindsay <i>[Signature]</i>	
DOB		Weight (kg)		Pharmacist: J. Sawyer/O. Okuwa Review by October 2015 Version 1					
Consultant		Surface Area (m <sup>2</sup> )		Allergies:					
Notes		<ul style="list-style-type: none"> <li>Mesna (3000mg/m<sup>2</sup>) to start after the completion of Ifosfamide &amp; Mesna infusions.</li> <li>Etoposide (100mg/m<sup>2</sup>) may be run concurrently with Mesna via separate lines, or administered after Mesna infusion is complete.</li> </ul>							
Day	Drug	Dose	Route	Infusion Duration	Administration Details	Batch No	Nurses Signature	Start Time	Stop Time
Day 3	Dexamethasone	8mg	po	stat					
.../.../...	Ondansetron	8mg	po	stat					
	MESNA (3000mg/m <sup>2</sup> )		iv	12 hours	NaCl 0.9% 1L				
	ETOPOSIDE (100mg/m <sup>2</sup> )		iv	60 min	NaCl 0.9% 500ml – 1000ml				
Prescriber's Signature & Date:				Pharmacist's Clinical Screen & Date:		Final release signature & Date:		Page 3 of 4	

Disclaimer: This document is for use only within Kent and Medway. No responsibility will be accepted for the accuracy of this information when used elsewhere.

Patient Name		<b>Kent &amp; Medway SACT proforma</b>				Date Calculated →		Protocol Number <b>HAEM-NHL-020</b>	
Patient Number		<p align="center"><b>ICE</b></p> <p align="center"><b>Non-Hodgkin's Lymphoma</b></p> <p align="center"><b>Curative / Non-curative / Remission</b></p> <p align="center">Cycle No.....</p> <p align="center">(Repeat every 21 days)</p> <p align="center">Length of cycle: 3 weeks</p> <p align="center">No. cycles: max 3</p>				Height (m)		Authorising Consultant: <i>S Rassam / J Lindsay</i>	
DOB						Weight (kg)		Pharmacist: <i>J Sawyer/O. Okuwa</i> Review by October 2015 Version 1	
Consultant		Surface Area (m <sup>2</sup> )		Allergies:					
Notes									
TTO MEDICATION		Drug	Dose	Route	Directions	Date	Quantity	Disp	Check
		Allopurinol	300mg	po	od for 3 weeks (first cycle only)				
		Metoclopramide	10mg	po	Up to tds regularly for 3 days, then 10mg up to tds PRN (28 tabs)				
		Co-trimoxazole	480mg	po	bd Mondays, Wednesdays, Fridays				
		Aciclovir	400mg	po	bd				
		Corsodyl Mouthwash	10ml	top	qds from day 1 of chemo				
		Itraconazole liquid	200mg	po	bd ongoing				
		Filgrastim	300 µg	sc	od days 6-13 of chemo				
Prescriber's Signature & Date:				Pharmacist's Clinical Screen & Date:		Final release signature & Date:		Page 4 of 4	

Disclaimer: This document is for use only within Kent and Medway. No responsibility will be accepted for the accuracy of this information when used elsewhere.